Goldman Sachs
GTBP icon

Goldman Sachs’s GT Biopharma GTBP Stock Holding History

Goldman Sachs’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30
Closed -$5.83K – 5688
2023
Q4 		$5.83K Buy
30
+16
+114% +$2.92K ﹤0.01% 5517
2023
Q3 		$2.51K Hold
14
– – ﹤0.01% 5470
2023
Q2 		$3.28K Hold
14
– – ﹤0.01% 5657
2023
Q1 		$5.78K Hold
14
– – ﹤0.01% 5784
2022
Q4 		$9.34K Sell
14
-19
-58% -$23.7K ﹤0.01% 5756
2022
Q3 		$44K Buy
33
+19
+136% +$36.3K ﹤0.01% 5817
2022
Q2 		$32K Hold
14
– – ﹤0.01% 6110
2022
Q1 		$31K Sell
14
-81
-85% -$179K ﹤0.01% 6345
2021
Q4 		$217K Buy
95
+25
+36% +$93.5K ﹤0.01% 5856
2021
Q3 		$353K Buy
+70
New +$527K ﹤0.01% 5403

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Goldman Sachs's GTBP Position: Q1 2024 in Review

Goldman Sachs sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 30 shares — an estimated $5.83K sold.

Goldman Sachs first reported a position in GTBP in Q3 2021 and held it in 10 quarters. The position peaked at $353K in Q3 2021. 11 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Goldman Sachs reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 30 GT Biopharma shares in Q1 2024, an estimated $5.83K.
  • Goldman Sachs first reported a position in GT Biopharma in Q3 2021 and held it in 10 quarters.
  • Goldman Sachs's GT Biopharma position peaked at $353K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.